Payment overview · 2025
General Payments
$995.37
45 reported records · 15 companies
Healthcare provider profile · identity verified
Amanda Raney
Allopathic & Osteopathic Physicians|Family Medicine · WICHITA, KS · NPI 1861050148
Verified facts
What the public records show
CMS Open Payments records show Amanda Raney received $995.37 in general payments during 2025 across 45 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $218.52 | 21.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $165.56 | 16.6% | 11 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$151.43 | 15.2% | 4 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $72.59 | 7.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $65.31 | 6.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.55 | 6.2% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $51.23 | 5.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.81 | 4.6% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $43.79 | 4.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.98 | 2.8% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.14 | 2.4% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $22.38 | 2.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.13 | 1.7% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $14.34 | 1.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.61 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $995.37 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $218.52 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $174.21 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $174.21 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $156.15 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $81.09 | 6 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $78.26 | 3 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $73.17 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $72.59 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $51.23 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.74 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.74 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.05 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $43.79 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $31.03 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $31.03 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $31.03 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $30.11 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $27.98 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $24.14 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $22.38 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $22.38 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $14.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 84 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
111 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 468 | 111 |
| Atorvastatin Calcium | Atorvastatin Calcium | 467 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 265 | 71 |
| Omeprazole | Omeprazole | 228 | 54 |
| Lisinopril | Lisinopril | 214 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 210 | 46 |
| Simvastatin | Simvastatin | 173 | 46 |
| Sertraline Hcl | Sertraline Hcl | 167 | 36 |
| Gabapentin | Gabapentin | 157 | 35 |
| Bupropion Xl | Bupropion Hcl | 147 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 141 | 27 |
| Losartan Potassium | Losartan Potassium | 133 | 40 |
| Potassium Chloride | Potassium Chloride | 133 | 35 |
| Trazodone Hcl | Trazodone Hcl | 133 | 24 |
| Alendronate Sodium | Alendronate Sodium | 131 | 43 |
| Furosemide | Furosemide | 131 | 31 |
| Eliquis | Apixaban | 111 | 18 |
| Metformin Hcl | Metformin Hcl | 96 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 89 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 22 |
| Ozempic | Semaglutide | 84 | 15 |
| Meloxicam | Meloxicam | 83 | 23 |
| Ezetimibe | Ezetimibe | 76 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 73 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 17 |
| Allopurinol | Allopurinol | 69 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 12 |
| Metformin Hcl Er | Metformin Hcl | 57 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | 16 |
| Carvedilol | Carvedilol | 51 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 47 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 39 |
| Estradiol | Estradiol | 47 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | 12 |
| Fluconazole | Fluconazole | 40 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 29 |
| Pregabalin | Pregabalin | 39 | suppressed |
| Lorazepam | Lorazepam | 38 | 14 |
| Montelukast Sodium | Montelukast Sodium | 38 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 11 |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Prednisone | Prednisone | 28 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 27 | 15 |
| Klor-Con M20 | Potassium Chloride | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 22 |
| Bumetanide | Bumetanide | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | suppressed |
| Ketoconazole | Ketoconazole | 18 | 14 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Famciclovir | Famciclovir | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 16 |
| Alprazolam | Alprazolam | 16 | suppressed |
| Azithromycin | Azithromycin | 16 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Sucralfate | Sucralfate | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $995.37 · 45 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BEYFORTUS, BREZTRI, COMIRNATY, Doc Band, ENTRESTO, EVENITY, FANAPT, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FREESTYLE LIBRE 3, GEMTESA, INTELLIS ADAPTIVESTIM, JARDIANCE, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, Prolastin-C Liquid, QULIPTA, Rybelsus, SYMPLICITY G3, UBRELVY, Wegovy, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error